비소세포폐암에서 면역관문억제제 반응 예측을 위한 인공지능 기반 PD-L1 종양 비율 점수 해석의 임상 검증

Kim 등(Wed,)이 이 문제를 연구하였습니다.

www.synapsesocial.com/papers/68e6c03bb6db64358763fab5 — DOI: https://doi.org/10.1200/po.23.00556

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response· 2022 · 61 citations
2. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation· 2019 · 265 citations
3. New Technology Add-On Payment (NTAP) for Viz LVO: a win for stroke care· 2020 · 45 citations
4. HER2 testing in gastric cancer: a practical approach· 2012 · 592 citations
5. AI in health and medicine· 2022 · 2,401 citations